Compare Natera Inc. Common Stock (NTRA) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.02 (market cap $330.26M). The key difference: Natera Inc. Common Stock is far larger — about 172.7× Roundhill S&P 500 0DTE Covered Call Strategy ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Roundhill S&P 500 0DTE Covered Call Strategy ETF for 56 Days on average.
| NTRA | XDTE | |
|---|---|---|
Market Cap | $57.03B | $330.26M |
Volume | 1,131,157 | 54,618 |
Sector | Health | Income / Options Overlay |
52-Week High | $425.64 | $44.76 |
52-Week Low | $179.42 | $36.00 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
XDTE (Roundhill S&P 500 0DTE Covered Call Strategy ETF) trades at $38.70 with no recent price movement. The technical picture appears bearish with moving averages signaling caution, while oscillators remain neutral. Recent news highlights concerns about the sustainability of XDTE's high yield strategy, with multiple articles questioning whether dividend payments represent true income or return of capital. The fund's weekly dividend payments range from $0.09 to $0.20, but analysts express skepticism about the underlying math.
The outlook for XDTE remains cautious as structural concerns about its covered call strategy persist. While the fund offers attractive weekly income, questions about yield sustainability and fee efficiency present significant risks. Investors should weigh the trade-offs between immediate income generation and potential long-term capital appreciation limitations in flat or rising markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
